CLINICAL_TRIALS
trial_result
· 2022-03-09
Clinical Trial Update: A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus [Phase 3]
Summary
A Phase 3 study of ustekinumab in active systemic lupus erythematosus was terminated, with results publicly posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Janssen Research & Development, LLC | Conditions: Lupus Erythematosus, Systemic | Phase 3 | Status: TERMINATED | Results posted: 2022-03-09